Taro Pharmaceutical Industries (NYSE:TARO) Hits New 1-Year Low at $27.50

Taro Pharmaceutical Industries Ltd. (NYSE:TAROGet Rating)’s share price hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $27.50 and last traded at $27.67, with a volume of 7150 shares. The stock had previously closed at $28.02.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on TARO shares. StockNews.com cut shares of Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Monday, October 31st. HC Wainwright cut their price objective on shares of Taro Pharmaceutical Industries from $73.00 to $54.00 and set a “buy” rating for the company in a report on Monday, August 15th.

Taro Pharmaceutical Industries Stock Performance

The business’s 50 day moving average price is $30.27 and its 200-day moving average price is $34.08. The firm has a market capitalization of $1.04 billion, a PE ratio of 15.99 and a beta of 0.65.

Institutional Investors Weigh In On Taro Pharmaceutical Industries

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Swiss National Bank grew its holdings in Taro Pharmaceutical Industries by 6.7% during the 1st quarter. Swiss National Bank now owns 22,300 shares of the company’s stock worth $965,000 after acquiring an additional 1,400 shares in the last quarter. Brandes Investment Partners LP boosted its holdings in shares of Taro Pharmaceutical Industries by 8.5% in the 1st quarter. Brandes Investment Partners LP now owns 379,322 shares of the company’s stock valued at $16,410,000 after buying an additional 29,606 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Taro Pharmaceutical Industries by 20.8% in the 1st quarter. American Century Companies Inc. now owns 6,048 shares of the company’s stock valued at $262,000 after buying an additional 1,043 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Taro Pharmaceutical Industries by 4.4% in the 1st quarter. US Bancorp DE now owns 10,487 shares of the company’s stock valued at $453,000 after buying an additional 444 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Taro Pharmaceutical Industries by 141.7% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 2,900 shares of the company’s stock valued at $125,000 after buying an additional 1,700 shares in the last quarter. 11.45% of the stock is owned by hedge funds and other institutional investors.

Taro Pharmaceutical Industries Company Profile

(Get Rating)

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products.

Recommended Stories

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.